Takeda taps Evox for exosome therapeutics 30-Mar-2020 By Ben Hargreaves The partners will focus on developing five potential exosome treatment for rare diseases.
Novartis’ gene therapy takes additional step towards EU approval 30-Mar-2020 By Ben Hargreaves Zolgensma has received a recommendation for approval despite running into problems recently, including manufacturing questions and data integrity issues.
Insulin designated biologic in ‘landmark moment’ 24-Mar-2020 By Ben Hargreaves Manufacturers can now apply to the US FDA for the approval of biosimilars to insulin products.
Univercells spins out viral vector CDMO to meet capacity demands 20-Mar-2020 By Vassia Barba Univercells announces the launch of Exothera, a CDMO focusing on viral vectors to support cell and gene therapy developers.
Pharma events update: rescheduled, canceled, online 18-Mar-2020 By Jenni Spinner This list includes the industry events that have been postponed or moved because of the coronavirus pandemic.
LSP closes European record $600m fund for life sciences 11-Mar-2020 By Ben Hargreaves In further positive signs for the European biotech market, LSP exceeds its funding target to raise largest ever sum in Europe.
Pharming receives US approval for expanded Ruconest production 11-Mar-2020 By Ben Hargreaves Following on from European approval, Pharming announces the US FDA has approved its new facility for the production of its Ruconest product.
In-PharmaTechnologist will soon be merging with Outsourcing-Pharma 09-Mar-2020 By Ben Hargreaves As of March 30, coverage previously found on in-PharmaTechnologist will be hosted by our sister website, Outsourcing-Pharma.
Diversity in biotech: Inclusion lower at higher levels 09-Mar-2020 By Vassia Barba Data published by BIO show diversity in biotech companies decreases at higher levels of management, especially in bigger, more profitable companies.
Samsung Biologics signs deal for development of next-gen PD-L1 04-Mar-2020 By Ben Hargreaves The Korean CDMO signs a partnership deal with STCube for the development of a STT-003 targeting antibody, which is approaching the IND stage.
Biogen dives deeper into Alzheimer’s with $350m deal 04-Mar-2020 By Ben Hargreaves Biogen signs a partnership agreement with Sangamo for the use of zinc-finger technology to progress various neurological disease candidates.
Gilead acquires oncology specialist Forty Seven in $4.9bn deal 03-Mar-2020 By Vassia Barba Gilead set to acquire Forty Seven in a $4.9bn deal to advance the developer’s lead mAb candidate, a potential cancer treatment.
George Scangos to lead BIO’s efforts against coronavirus 02-Mar-2020 By Ben Hargreaves The ex-Biogen CEO will coordinate the biotech organization’s response to the virus.
Biocon insulin facility hit with FDA Form 483 27-Feb-2020 By Ben Hargreaves Biocon’s Malaysia facility received a Form 483 with three observations, after a pre-approval inspection.
Securecell extends reach in Asia, Israel 27-Feb-2020 By Jenni Spinner The biopharma solutions firm is expanding its footprint with new sales and marketing partners in China, Korea and Israel.
